CN Announces Janet Drysdale as Interim Chief Commercial Officer
MONTREAL, July 21, 2025 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) announced today that Janet Drysdale will assume the role of Chief Commercial Officer on an interim basis, effective immediately. Janet is stepping into the role following the departure of Remi G. Lalonde.
Janet spent the first decade of her nearly 30-year career at CN in a variety of roles in Sales and Marketing. She is a seasoned and versatile leader with significant cross-functional experience having held executive positions at CN in Investor Relations, Finance, Corporate/Business Development, Sustainability, and most recently as Chief Stakeholder Relations Officer. "I am very pleased that Janet will be leading our commercial team during this critical time. Janet's depth of experience in sales and marketing, steady hand, and drive for results will provide strong leadership for the commercial team. I look forward to working closely with her as we accelerate the execution of our growth agenda,' said Tracy Robinson, President and Chief Executive Officer at CN. "I thank Remi for his contributions to CN."
The Chief Commercial Officer role is a critical executive position overseeing CN's strong and experienced team responsible for sales and marketing. The appointment of a permanent Chief Commercial Officer is a priority.
Biographical Notes Janet is an independent director of Rumo S.A., Brazil's largest freight railway. She is Chair of the Board of the Railway Association of Canada, and she sits on the Board of the Canadian American Business Council.
Ms. Drysdale holds an Honours Bachelor of Science degree from Queen's University and an MBA from McGill University. Ms. Drydale also holds the Global Competent Boards Designation (GCB.D).
About CNCN powers the economy by safely transporting more than 300 million tons of natural resources, manufactured products, and finished goods throughout North America every year for its customers. With its nearly 20,000-mile rail network and related transportation services, CN connects Canada's Eastern and Western coasts with the U.S. Midwest and the U.S. Gulf Coast, contributing to sustainable trade and the prosperity of the communities in which it operates since 1919.
Jonathan Abecassis
Stacy Alderson
Director, Public Affairs and
Assistant Vice-President
Media Relations
Investor Relations
(438) 455-3692
(514) 399-0052
media@cn.ca
investor.relations@cn.ca
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News24
2 hours ago
- News24
Three more people arrested in R300m West Coast shareholder fraud case
Three more people have appeared in the Vredenburg Magistrate's Court in connection with a R300 million shareholder fraud case, bringing the total number of accused to 10. Hawks spokesperson Warrant Officer Zinzi Hani said the unit's Serious Commercial Crime Investigation team in Bellville arrested Benjamin Burger Lubbe, 85, Nicolaas Jacobus Latsky, 77, and Petrus Van Eeden Marais, 64, for fraud, contravention of the Financial Markets Act and contravention of the Companies Act. They appeared in the Vredenburg Magistrate's Court on Tuesday and were released on R10 000 bail each. They will join their seven co-accused, who were arrested in May. The seven are Jacobus Francois Pienaar, 69, Andries Johannes Frederick Eigelaar, 75, Carel Johannes Hendrik Mienie, 56, Carel Johannes Daniel Eigelaar, 70, Meiring Tarrant, 55, Minette Louw, 44, and Albert Johannes Marais, 68. Among them are three lawyers, two auditors, directors and senior officials of associated accused companies. The seven are out on bail of R10 000 each. The case dates back to 2006, when the accused - majority shareholders - allegedly defrauded minority shareholders by manipulating share prices, causing a loss of an estimated R300 million, Hani said. All ten accused will appear in court again on 21 November.
Yahoo
3 hours ago
- Yahoo
Asian Stocks Estimated To Be 12.7% To 26.2% Below Intrinsic Value
As global markets respond to favorable trade deal news, Asian equities have shown resilience amid ongoing tariff discussions and economic uncertainties. In this environment, identifying undervalued stocks—those trading below their intrinsic value—can offer potential opportunities for investors looking to capitalize on market inefficiencies. Top 10 Undervalued Stocks Based On Cash Flows In Asia Name Current Price Fair Value (Est) Discount (Est) Shin Maint HoldingsLtd (TSE:6086) ¥1174.00 ¥2321.82 49.4% Shenzhen KSTAR Science and Technology (SZSE:002518) CN¥23.34 CN¥46.18 49.5% Range Intelligent Computing Technology Group (SZSE:300442) CN¥51.15 CN¥101.32 49.5% Polaris Holdings (TSE:3010) ¥220.00 ¥433.40 49.2% Nan Ya Printed Circuit Board (TWSE:8046) NT$177.00 NT$350.10 49.4% LigaChem Biosciences (KOSDAQ:A141080) ₩139000.00 ₩277490.02 49.9% Hibino (TSE:2469) ¥2345.00 ¥4664.61 49.7% Heartland Group Holdings (NZSE:HGH) NZ$0.82 NZ$1.62 49.4% Forum Engineering (TSE:7088) ¥1206.00 ¥2405.10 49.9% Andes Technology (TWSE:6533) NT$274.50 NT$542.92 49.4% Click here to see the full list of 265 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Below we spotlight a couple of our favorites from our exclusive screener. Dongsung FineTec Overview: Dongsung FineTec Co., Ltd. is a South Korean company that manufactures and sells cryogenic insulation products, with a market cap of approximately ₩811.48 billion. Operations: The company's revenue segments include the Gas Business, generating approximately ₩23.03 billion, and Cooling Material, contributing around ₩609.47 billion. Estimated Discount To Fair Value: 26.2% Dongsung FineTec is trading at ₩27,950, significantly undervalued compared to its estimated fair value of ₩37,869.08. Its earnings are projected to grow at 22.6% annually, outpacing the Korean market's growth rate and reflecting robust financial health despite an unstable dividend track record. Recent quarterly results showed net income of KRW 9 billion, up from KRW 8.69 billion a year earlier, reinforcing its strong cash flow position in the Asian market. Our growth report here indicates Dongsung FineTec may be poised for an improving outlook. Click to explore a detailed breakdown of our findings in Dongsung FineTec's balance sheet health report. Nanjing Vazyme Biotech Overview: Nanjing Vazyme Biotech Co., Ltd provides technology solutions in life science, biomedicine, and in vitro diagnostics with a market cap of CN¥10.52 billion. Operations: Nanjing Vazyme Biotech Co., Ltd generates revenue through its technology solutions in life science, biomedicine, and in vitro diagnostics. Estimated Discount To Fair Value: 17.1% Nanjing Vazyme Biotech is trading at CN¥26.44, slightly below its fair value estimate of CN¥31.91, suggesting it may be undervalued based on cash flows. The company is expected to become profitable within three years, with earnings projected to grow 78.27% annually—surpassing market averages despite a low forecasted return on equity of 5.6%. A recent share buyback plan worth CN¥10 million aims to enhance shareholder value through potential equity incentives or employee stock ownership plans. Our expertly prepared growth report on Nanjing Vazyme Biotech implies its future financial outlook may be stronger than recent results. Delve into the full analysis health report here for a deeper understanding of Nanjing Vazyme Biotech. Zhejiang Yinlun MachineryLtd Overview: Zhejiang Yinlun Machinery Co., Ltd. focuses on the research, development, manufacturing, and sale of thermal management and exhaust gas post-treatment products, with a market cap of CN¥24.97 billion. Operations: The company generates revenue primarily from the sale of thermal management and exhaust gas post-treatment products. Estimated Discount To Fair Value: 12.7% Zhejiang Yinlun Machinery is trading at CN¥30.13, undervalued relative to its fair value estimate of CN¥34.53. Earnings grew 18.9% last year and are projected to rise 25.12% annually, outpacing the Chinese market's growth rate of 23.5%. Despite a lower future return on equity forecast of 16.1%, recent share buybacks totaling CN¥34.96 million may enhance shareholder value through equity incentives or employee stock ownership plans. According our earnings growth report, there's an indication that Zhejiang Yinlun MachineryLtd might be ready to expand. Click here and access our complete balance sheet health report to understand the dynamics of Zhejiang Yinlun MachineryLtd. Make It Happen Reveal the 265 hidden gems among our Undervalued Asian Stocks Based On Cash Flows screener with a single click here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Interested In Other Possibilities? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSDAQ:A033500 SHSE:688105 and SZSE:002126. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
High Growth Tech Stocks in Asia Featuring Three Prominent Picks
As global markets experience a surge, with key indices like the S&P 500 and Nasdaq Composite reaching record highs due to favorable trade deals, the Asian tech sector is also capturing attention amidst hopes for extended tariff truces and economic growth. In this dynamic environment, identifying high-growth tech stocks involves looking at companies that are well-positioned to leverage technological advancements and capitalize on improving trade relations. Top 10 High Growth Tech Companies In Asia Name Revenue Growth Earnings Growth Growth Rating Accton Technology 22.05% 23.29% ★★★★★★ Gold Circuit Electronics 20.97% 26.54% ★★★★★★ Zhejiang Lante Optics 21.61% 23.73% ★★★★★★ PharmaEssentia 31.60% 57.71% ★★★★★★ Fositek 30.51% 37.34% ★★★★★★ Eoptolink Technology 32.53% 32.58% ★★★★★★ Zhejiang Meorient Commerce Exhibition 26.71% 35.89% ★★★★★★ eWeLLLtd 24.95% 24.40% ★★★★★★ Shengyi Electronics 26.23% 37.40% ★★★★★★ CARsgen Therapeutics Holdings 81.53% 96.08% ★★★★★★ Click here to see the full list of 168 stocks from our Asian High Growth Tech and AI Stocks screener. Here's a peek at a few of the choices from the screener. Gan & Lee Pharmaceuticals Simply Wall St Growth Rating: ★★★★☆☆ Overview: Gan & Lee Pharmaceuticals is a biopharmaceutical company focused on the research, development, production, and sale of insulin analog APIs and injections in China with a market cap of approximately CN¥36.43 billion. Operations: Gan & Lee Pharmaceuticals primarily generates revenue through the development, production, and sale of insulin and related products, amounting to approximately CN¥3.47 billion. The company's operations are centered in China, focusing on biopharmaceutical advancements in insulin analogs. Gan & Lee Pharmaceuticals, a trailblazer in diabetes care, recently secured approval for its insulin aspart injection in Argentina, signaling robust expansion within Latin America's critical healthcare markets. This strategic move aligns with the rising demand for cost-effective diabetes treatments in regions grappling with high diabetes prevalence and healthcare costs. Impressively, Gan & Lee's revenue and earnings have been outpacing the Chinese market with annual increases of 19.5% and 26.8%, respectively. The firm's commitment to innovation is underscored by its R&D spending, which has consistently amplified its product pipeline and market competitiveness. Get an in-depth perspective on Gan & Lee Pharmaceuticals' performance by reading our health report here. Evaluate Gan & Lee Pharmaceuticals' historical performance by accessing our past performance report. Wuhan Dameng Database Simply Wall St Growth Rating: ★★★★☆☆ Overview: Wuhan Dameng Database Company Limited specializes in database product development services within China and has a market cap of CN¥26.47 billion. Operations: The company generates revenue primarily from data processing services, amounting to CN¥1.14 billion. Wuhan Dameng Database has demonstrated robust growth, with a notable 22.6% annual revenue increase and an earnings surge of 28.3% over the past year, outpacing the broader Chinese software industry's average. This performance is underpinned by strategic shareholder decisions, such as the recent approval of a significant financial cooperation agreement, enhancing its competitive edge in tech innovation. The company also prioritizes R&D investments, ensuring sustained advancement and market relevance in a rapidly evolving digital landscape. Unlock comprehensive insights into our analysis of Wuhan Dameng Database stock in this health report. Examine Wuhan Dameng Database's past performance report to understand how it has performed in the past. Dongguan Tarry ElectronicsLtd Simply Wall St Growth Rating: ★★★★★☆ Overview: Dongguan Tarry Electronics Co., Ltd. operates in China, producing and distributing precision die cutting products, foam protective film tapes, insulation heat conduction products, EMI shielding products, sewing and high frequency earmuffs, headbands, and assembly automation equipment with a market cap of CN¥7.35 billion. Operations: The company generates revenue primarily from its manufacturing industry segment, which accounts for CN¥2.77 billion. Its diverse product offerings include precision die cutting products and EMI shielding solutions. Dongguan Tarry Electronics has carved a niche in the high-growth tech sector in Asia, with a remarkable annual revenue growth of 23.6% and earnings growth of 26.6%. This performance is bolstered by its strategic focus on R&D, spending significantly to stay ahead in innovation within the electronics industry where it outperformed sector growth by over 160% last year. Recent corporate activities including leadership changes and shareholder meetings suggest proactive governance, poised to sustain its competitive edge and drive future growth amidst evolving market demands. Navigate through the intricacies of Dongguan Tarry ElectronicsLtd with our comprehensive health report here. Explore historical data to track Dongguan Tarry ElectronicsLtd's performance over time in our Past section. Seize The Opportunity Click here to access our complete index of 168 Asian High Growth Tech and AI Stocks. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Curious About Other Options? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:603087 SHSE:688692 and SZSE:300976. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
